Calidi Biotherapeutics Prices Public Offering at $0.50 per Unit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy CLDI?
Source: NASDAQ.COM
- Public Offering Pricing: Calidi Biotherapeutics has priced its public offering at $0.50 per unit for 10.52 million units, expecting gross proceeds of approximately $5.2 million, which will support working capital and general corporate purposes.
- Warrant Structure: Each unit consists of one share of common stock or a pre-funded warrant, and the company has granted the underwriter a 45-day option to purchase up to 1.575 million shares to cover over-allotments, demonstrating flexibility in response to market demand.
- Warrant Amendment: Existing warrants held by investors for up to 2.973 million shares will be amended to reduce the exercise price to $0.50 per share upon closing of the offering, aimed at enhancing investor appeal and boosting market confidence.
- Market Reaction: Despite Calidi's stock closing down 53.14% at $0.36 last Friday and further declining to $0.35 in after-hours trading, the successful execution of this offering may provide essential funding for the company's future R&D efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLDI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLDI
About CLDI
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Calidi Biotherapeutics Prices Public Offering at $0.50 per Unit
- Public Offering Pricing: Calidi Biotherapeutics has priced its public offering at $0.50 per unit for 10.52 million units, expecting gross proceeds of approximately $5.2 million, which will support working capital and general corporate purposes.
- Warrant Structure: Each unit consists of one share of common stock or a pre-funded warrant, and the company has granted the underwriter a 45-day option to purchase up to 1.575 million shares to cover over-allotments, demonstrating flexibility in response to market demand.
- Warrant Amendment: Existing warrants held by investors for up to 2.973 million shares will be amended to reduce the exercise price to $0.50 per share upon closing of the offering, aimed at enhancing investor appeal and boosting market confidence.
- Market Reaction: Despite Calidi's stock closing down 53.14% at $0.36 last Friday and further declining to $0.35 in after-hours trading, the successful execution of this offering may provide essential funding for the company's future R&D efforts.
See More
Calidi Biotherapeutics Completes $6 Million Public Offering
- Funding Amount: Calidi Biotherapeutics successfully raised approximately $6 million through its public offering and the underwriters' over-allotment option, demonstrating market confidence in its genetic therapy technology and strengthening the financial foundation for future R&D.
- Stock Issuance Details: The offering included 12,094,631 shares of common stock along with Series J, K, and L warrants, reflecting investor confidence in the company's growth potential and providing necessary funding for upcoming clinical trials.
- Warrant Details: The Series J, K, and L warrants were issued with an initial exercise price of $0.50 per share and varying expiration terms, ensuring investor flexibility while also presenting potential capital appreciation opportunities for the company.
- Platform Advantage: Calidi's Redtail platform focuses on targeted therapies and is currently undergoing IND-enabling studies for non-small cell lung cancer and other high unmet medical need tumor types, showcasing the company's innovative capabilities and competitive edge in the biotechnology sector.
See More
U.S. Stocks Decline Amid Weak Retail Sales Data
- Market Performance: U.S. stocks broadly declined during trading, with the S&P 500 falling approximately 1%, the Dow down 0.99% to 47,479.25, and the NASDAQ dropping 0.86% to 22,554.26, indicating market concerns over economic outlook.
- Retail Sales Data: U.S. retail sales fell by 0.2% month-over-month in January, missing market estimates of a 0.3% decline, reflecting weak consumer spending that could negatively impact economic growth.
- Sector Movements: While the overall market declined, energy stocks rose by 0.5%, contrasting with a 2.1% drop in financial stocks, indicating sector divergence that may influence investor asset allocation strategies.
- International Market Dynamics: European shares fell broadly, with the eurozone's STOXX 600 down 1.04%, while Asian markets mostly gained, suggesting varying performances across regions that could affect global investor confidence.
See More
Calidi Biotherapeutics Prices Public Offering of 10.52M Units
- Offering Size: Calidi Biotherapeutics announced the pricing of 10.52 million units at $0.50 each, expecting to raise approximately $5.2 million in gross proceeds for working capital and general corporate purposes after underwriting discounts and expenses.
- Underwriting Arrangement: Ladenburg Thalmann & Co. Inc. is acting as the sole book-running manager for the offering, granting underwriters a 45-day option to purchase up to 1.575 million additional shares and warrants, enhancing market liquidity.
- Warrant Terms: Each unit consists of one share of common stock and three warrants exercisable over six months, twelve months, and five years, aimed at attracting investors and enhancing shareholder value.
- Existing Warrant Amendment: The company agreed to amend existing warrants to reduce the exercise price to $0.50 per share upon the offering's closing, further boosting investor confidence and optimizing capital structure.
See More
U.S. Stocks Decline as Unemployment Rate Rises
- Market Weakness: U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 300 points and the S&P 500 dropping 1.38% to 6,736.10, reflecting investor concerns over economic data that may impact market confidence.
- Nonfarm Payrolls Decline: The Bureau of Labor Statistics reported a loss of 92,000 nonfarm payrolls in February 2026, significantly below economists' expectations of 59,000, indicating signs of economic slowdown that could lead to further market volatility.
- Unemployment Rate Increase: The unemployment rate unexpectedly ticked up to 4.4%, surpassing forecasts of 4.3%, which may raise concerns about economic recovery and affect consumer spending and business investment.
- Energy Stocks Resilience: Despite the overall market decline, energy shares rose by 1%, indicating that certain sectors are showing resilience in an uncertain economic environment, potentially attracting investor interest.
See More
Calidi Biotherapeutics Prices Public Offering of 10.5 Million Units
- Offering Size: Calidi Biotherapeutics announced the pricing of its public offering of 10,519,631 units at $0.50 per unit, with expected gross proceeds of approximately $5.2 million, reflecting the company's proactive financing strategy in the capital markets.
- Warrant Structure: Each unit consists of one share of common stock and three different warrants with varying terms of 6 months, 12 months, and 5 years, designed to attract investors and enhance liquidity, thereby increasing shareholder value.
- Over-Allotment Option: The underwriter has a 45-day option to purchase up to an additional 1,575,000 shares, which further boosts market confidence in Calidi and provides flexibility for future financing.
- Use of Proceeds: The net proceeds from the offering will be used for working capital and general corporate purposes, indicating the company's strategic decision to advance its gene therapy research and market expansion efforts.
See More
Calidi Biotherapeutics Prices Public Offering at $0.50 per Unit
- Public Offering Pricing: Calidi Biotherapeutics has priced its public offering at $0.50 per unit for 10.52 million units, expecting gross proceeds of approximately $5.2 million, which will support working capital and general corporate purposes.
- Warrant Structure: Each unit consists of one share of common stock or a pre-funded warrant, and the company has granted the underwriter a 45-day option to purchase up to 1.575 million shares to cover over-allotments, demonstrating flexibility in response to market demand.
- Warrant Amendment: Existing warrants held by investors for up to 2.973 million shares will be amended to reduce the exercise price to $0.50 per share upon closing of the offering, aimed at enhancing investor appeal and boosting market confidence.
- Market Reaction: Despite Calidi's stock closing down 53.14% at $0.36 last Friday and further declining to $0.35 in after-hours trading, the successful execution of this offering may provide essential funding for the company's future R&D efforts.
See More
Calidi Biotherapeutics Completes $6 Million Public Offering
- Funding Amount: Calidi Biotherapeutics successfully raised approximately $6 million through its public offering and the underwriters' over-allotment option, demonstrating market confidence in its genetic therapy technology and strengthening the financial foundation for future R&D.
- Stock Issuance Details: The offering included 12,094,631 shares of common stock along with Series J, K, and L warrants, reflecting investor confidence in the company's growth potential and providing necessary funding for upcoming clinical trials.
- Warrant Details: The Series J, K, and L warrants were issued with an initial exercise price of $0.50 per share and varying expiration terms, ensuring investor flexibility while also presenting potential capital appreciation opportunities for the company.
- Platform Advantage: Calidi's Redtail platform focuses on targeted therapies and is currently undergoing IND-enabling studies for non-small cell lung cancer and other high unmet medical need tumor types, showcasing the company's innovative capabilities and competitive edge in the biotechnology sector.
See More
U.S. Stocks Decline Amid Weak Retail Sales Data
- Market Performance: U.S. stocks broadly declined during trading, with the S&P 500 falling approximately 1%, the Dow down 0.99% to 47,479.25, and the NASDAQ dropping 0.86% to 22,554.26, indicating market concerns over economic outlook.
- Retail Sales Data: U.S. retail sales fell by 0.2% month-over-month in January, missing market estimates of a 0.3% decline, reflecting weak consumer spending that could negatively impact economic growth.
- Sector Movements: While the overall market declined, energy stocks rose by 0.5%, contrasting with a 2.1% drop in financial stocks, indicating sector divergence that may influence investor asset allocation strategies.
- International Market Dynamics: European shares fell broadly, with the eurozone's STOXX 600 down 1.04%, while Asian markets mostly gained, suggesting varying performances across regions that could affect global investor confidence.
See More
Calidi Biotherapeutics Prices Public Offering of 10.52M Units
- Offering Size: Calidi Biotherapeutics announced the pricing of 10.52 million units at $0.50 each, expecting to raise approximately $5.2 million in gross proceeds for working capital and general corporate purposes after underwriting discounts and expenses.
- Underwriting Arrangement: Ladenburg Thalmann & Co. Inc. is acting as the sole book-running manager for the offering, granting underwriters a 45-day option to purchase up to 1.575 million additional shares and warrants, enhancing market liquidity.
- Warrant Terms: Each unit consists of one share of common stock and three warrants exercisable over six months, twelve months, and five years, aimed at attracting investors and enhancing shareholder value.
- Existing Warrant Amendment: The company agreed to amend existing warrants to reduce the exercise price to $0.50 per share upon the offering's closing, further boosting investor confidence and optimizing capital structure.
See More
U.S. Stocks Decline as Unemployment Rate Rises
- Market Weakness: U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 300 points and the S&P 500 dropping 1.38% to 6,736.10, reflecting investor concerns over economic data that may impact market confidence.
- Nonfarm Payrolls Decline: The Bureau of Labor Statistics reported a loss of 92,000 nonfarm payrolls in February 2026, significantly below economists' expectations of 59,000, indicating signs of economic slowdown that could lead to further market volatility.
- Unemployment Rate Increase: The unemployment rate unexpectedly ticked up to 4.4%, surpassing forecasts of 4.3%, which may raise concerns about economic recovery and affect consumer spending and business investment.
- Energy Stocks Resilience: Despite the overall market decline, energy shares rose by 1%, indicating that certain sectors are showing resilience in an uncertain economic environment, potentially attracting investor interest.
See More
Calidi Biotherapeutics Prices Public Offering of 10.5 Million Units
- Offering Size: Calidi Biotherapeutics announced the pricing of its public offering of 10,519,631 units at $0.50 per unit, with expected gross proceeds of approximately $5.2 million, reflecting the company's proactive financing strategy in the capital markets.
- Warrant Structure: Each unit consists of one share of common stock and three different warrants with varying terms of 6 months, 12 months, and 5 years, designed to attract investors and enhance liquidity, thereby increasing shareholder value.
- Over-Allotment Option: The underwriter has a 45-day option to purchase up to an additional 1,575,000 shares, which further boosts market confidence in Calidi and provides flexibility for future financing.
- Use of Proceeds: The net proceeds from the offering will be used for working capital and general corporate purposes, indicating the company's strategic decision to advance its gene therapy research and market expansion efforts.
See More
